Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 R...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2024-01, Vol.109 (1), p.4-9
Hauptverfasser:	Ferreira, João Pedro, Sharma, Abhinav, Butler, Javed, Packer, Milton, Zannad, Faiez, Vasques-Nóvoa, Francisco, Leite-Moreira, Adelino, Neves, João Sérgio
Format:	Artikel
Sprache:	eng
Schlagworte:	Arrhythmia Body weight Cardiovascular Diseases - chemically induced Diabetes Mellitus, Type 2 - chemically induced Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Glucagon Glucagon-Like Peptide 1 - metabolism Glucagon-Like Peptide-1 Receptor - agonists Heart Heart attack Heart failure Heart Failure - diagnosis Humans Hypoglycemic agents Hypoglycemic Agents - adverse effects Life Sciences Natriuretic peptides Risk Factors Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!